3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Sezary Syndrome
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Leukemia
1
Interventions
Dexamethasone
8
Cytarabine
7
Cyclophosphamide
7
venetoclax
6
Vincristine
6
Methotrexate
5
merphos
4
Rituximab
4
Prednisone
4
pegaspargase
3
fludarabine phosphate
3
dexamethasone acetate
3
dexamethasone 21-phosphate
3
Peripheral Blood Stem Cell Transplantation
3
Filgrastim
3
Calcium Dobesilate
3
ruxolitinib
2
prednylidene
2
nelarabine
2
deltacortene
2
auricularum
2
Whole-Body Irradiation
2
Specimen Handling
2
Pentetic Acid
2
Mycophenolic Acid
2
Injections
2
Granulocyte Colony-Stimulating Factor
2
Everolimus
2
Etoposide
2
Decitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
×
navitoclax
×
Clear all
NCT05740449
2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2
Withdrawn